Inmune Bio Inc. · NASDAQ:INMB
Inmune Bio — Innate Killer Summit March 2025
16 slides from Inmune Bio's conference presentation, Mar 4, 2025
Slide 1: In vivo activation of mlNK cells with INKmune
INMB Nasdaq In vivo activation of mlNK cells with INKmune Preliminary results from a phase I/II trial in metastatic, castration - resistant prostate cancer Mark Lowdell CSO INmuneBio Inc INMB Nasdaq Innate Killer Summit March 2025
Slide 2: Forward Looking Statements
2 FORWARD LOOKING STATEMENTS This presentation contains “forward - looking statements” Forward - looking statements reflect our current view about future events. When used in this presentation, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of th
Slide 3: Evidence for tumor-primed mlNK
3 Evidence for tumor - primed mlNK
Slide 4: MoA of INKmune: NK-tumor trogocytosis
4 NK - Tumor TROGOCYTOSIS Resting NK Resting NK o/n TpNK o/n MoA of INKmune
Slide 5: CaPr TiML NK target solid tumors
5 R a j i D A U D I S K O V 3 S K O V 3 S K O V 3 7 6 8 O 7 6 8 O 7 6 8 O 7 6 8 O 7 6 8 O 7 6 8 O 7 6 8 O 7 6 8 O 7 6 8 O M D S - L M D S - L M D S - L M D S - L M D S - L 0 20 40 60 80 100 % s p e c i f i c l y s i s rNK TpNK Ovarian cancer patients Renal Cell cancer patients MDS patients R a j i 7
Slide 6: INKmune potential MoA
6 INKmune potential MoA rNK LAK - 15 CIML - NK INKMUNE - TpNK proteomics G A T B G A T C G F M 2 H A R S 1 H A R S 2 L A R S 2 M R P L 1 0 M R P L 1 6 M R P L 2 M R P L 2 3 M R P L 4 7 M R P L 5 1 M R P L 5 7 M R P S 1 1 M R P S 1 2 M R P S 1 5 M R P S 1 6 M R P S 1 7 M R P S 1 8 A M R P S 1 8 B M R
Slide 7: INKmune-mediated effects on mitochondrial function and nutrient receptors
7 Rapid proliferation of NK cells ex - vivo leads to reduced mitochondrial fitness; decreased membrane potential and increased levels of mitochondrial reactive oxygen species ( mtROS ) Mitochondrial fitness has to be restored for the persistence of long - term NK cell function; this is achieved by m
Slide 8: INKmune mCRPC Phase I/II Trial Design
8 INKmune mCRPC Phase I/II Trial Design Low - dose 1x10 8 Middle - dose 3x10 8 High - dose 5 x10 8 1 1 1 1 1 1 1 1 1 Step 1: Short term safety Immunologic efficacy 6 patients 6 patients Step 2: Long term safety Immunologic efficacy Anti - tumor effects 6 patients Confirmatory group In this example:
Slide 9: CARE-PC clinical sites
CARE - PC – clinical sites PI Name Location Site Name Site Number Matthew Rettig Los Angeles, CA VA Greater Los Angeles Healthcare 101 Alexander Starodub Cincinnati, OH The Christ Hospital 102 Matthew Rettig Los Angeles, CA UCLA 103 Bruce Montgomery Seattle, WA Puget Sound VA 104 Mary Crow The Woodl
Slide 10: CARE-PC data to be presented
CARE - PC – data to be presented Confidential 9.30.20 v3 10 Month 6 Month 3 Pre Dose Level Subject x x x 1 D1 - 001 x x x 1 D1 - 002 x x x 1 D1 - 003 PD x x 2 D2 - 001 Awaited x x 2 D2 - 002 PD x x 2 D2 - 003 PD x x 3 D3 - 001
Slide 11: CARE-PC March 2025
CARE - PC March 2025 • All phase I doses administered – No AE/SAE/SAR after 29 infusions in 10 patients at all three doses – Primary safety end - point met • Phase II open at intermediate and high doses – 2 patients at intermediate level treated • CMC completed for all future doses • Immune response
Slide 12: Potency Assay Summary by Patient
12 Potency Assay Summary for Patient 102-001 0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 1 1 0 1 2 0 1 3 0 1 4 0 1 5 0 1 6 0 1 7 0 0 10 20 30 40 50 60 70 80 90 100 0 50 100 150 200 250 300 NK/mL whole blood Raji KillingK562 Killing Day P e r c e n t a g e ( % ) N K / L w h o l e b l o o d Potency As
Slide 13: NK activation in vivo
13 NK activation in vivo 18 1 5 2 9 5 7 8 5 1 1 3 1 4 1 1 6 9 18 1 5 2 9 5 7 8 5 1 1 3 1 4 1 1 6 9 18 1 5 2 9 5 7 8 5 1 1 3 1 4 1 1 6 9 18 1 5 2 9 5 7 8 5 1 1 3 1 4 1 1 6 9 18 1 5 2 9 5 7 8 5 1 1 3 1 4 1 1 6 9 18 1 5 2 9 5 7 8 5 1 1 3 1 4 1 1 6 9 0 10 20 30 40 50 CD16 low DAYS % o f N K D1-001 D1-00
Slide 14: Whole body tumour volume
14 L1 L1 L1 L2 L2 L2 L3 Baseline Day 57 Day 169 L3 L1 L1 L1 L2 L2 L2 Whole body tumour volume Average tumour volume per site Baseline Day 57 Day 169
Slide 15: CARE-PC Conclusions
CARE - PC Conclusions • Primary safety end - point met • Evidence of NK activation in vivo even at lowest dose • Transient effects on tumor lesions – LN mets might be most sensitive • No consistent effect on PSA – immunoRx not expected to do so • ctDNA data awaited • High level disease burden probab
Slide 16: Acknowledgements
Acknowledgements • INmuneBio – Dr Ben Weil – UK CMC/GMP team – CARE - PC clinical ops team • US investigators – Dr Matt Rettig - UCLA